Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cigna GroupCI · Entity 550 | See Remarks | July 01, 2026 | July 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cigna Group
Report date July 01, 2026 · Filed July 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $.01 Par ValueSEC Table I · non-derivative | Direct | 34,705 |
Reported balance
Holding disclosure · report date 2026-07-01 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 34,705 |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $294.61 · Expires 2033-02-22 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-07-01 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F1: This option vested in three equal annual installments beginning March 1, 2024. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $336.48 · Expires 2034-02-28 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-07-01 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F2: This option vests in three equal annual installments beginning March 1, 2025. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $305.86 · Expires 2035-02-28 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-07-01 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance Not disclosed F3: This option vests in three equal annual installments beginning March 1, 2026. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $287.55 · Expires 2036-02-27 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-07-01 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance Not disclosed F4: This option vests in three equal annual installments beginning March 1, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: This option vested in three equal annual installments beginning March 1, 2024.
F2: This option vests in three equal annual installments beginning March 1, 2025.
F3: This option vests in three equal annual installments beginning March 1, 2026.
F4: This option vests in three equal annual installments beginning March 1, 2027.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Cigna Holding Co
Report date December 20, 2018 · Filed December 26, 2018
Section 16 reporting ended · disclosed 2018-12-26. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $.25 Par ValueSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-12-20 transaction · row 1
1 source rowRow 1 · 2018-12-20 · Disposition to issuer · Disposed 25,339 · Balance 0 F1: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote) F2: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $139.22 · Expires 2026-03-01 | Direct | 0 |
Reported balance
After 2018-12-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-12-20 · Disposition to issuer · Disposed 4,562 · Balance 0 F1: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote) F2: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F6: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F3: Two-thirds of this option was vested at the time of the Merger. The option was assumed by New Cigna in the Merger and converted into an option to purchase an equal number of shares of New Cigna Common Stock for $139.22 per share, with the remaining one-third of the option vesting on March 1, 2019. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $149.14 · Expires 2027-02-28 | Direct | 0 |
Reported balance
After 2018-12-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-12-20 · Disposition to issuer · Disposed 12,402 · Balance 0 F1: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote) F2: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F6: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F4: One-third of this option was vested at the time of the Merger. The option was assumed by New Cigna in the Merger and converted into an option to purchase an equal number of shares of New Cigna Common Stock for $149.135 per share, with the remaining two-thirds of the option vesting in two equal installments on February 28, 2019 and February 28, 2020. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $197.35 · Expires 2028-02-28 | Direct | 0 |
Reported balance
After 2018-12-20 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-12-20 · Disposition to issuer · Disposed 12,271 · Balance 0 F1: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote) F2: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F6: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F5: This option, which would have vested in three equal installments beginning on February 28, 2019, was assumed by New Cigna in the Merger and converted into an option to purchase an equal number of shares of New Cigna Common Stock for $197.35 per share on the same vesting terms. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote)
F2: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30.
F3: Two-thirds of this option was vested at the time of the Merger. The option was assumed by New Cigna in the Merger and converted into an option to purchase an equal number of shares of New Cigna Common Stock for $139.22 per share, with the remaining one-third of the option vesting on March 1, 2019.
F4: One-third of this option was vested at the time of the Merger. The option was assumed by New Cigna in the Merger and converted into an option to purchase an equal number of shares of New Cigna Common Stock for $149.135 per share, with the remaining two-thirds of the option vesting in two equal installments on February 28, 2019 and February 28, 2020.
F5: This option, which would have vested in three equal installments beginning on February 28, 2019, was assumed by New Cigna in the Merger and converted into an option to purchase an equal number of shares of New Cigna Common Stock for $197.35 per share on the same vesting terms.
F6: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 02, 2018 Filed Nov 6, 2018 18:13 UTC | Cigna Holding Co CI · Entity 161580 | Exercise / conversionCommon Stock, $.25 Par Value | 4,562 | $139.22 | $635,121.64 |
DisclosureSEC source: 0001225208-18-015237 · doc4.xml · nonDerivative · entry 2 Sadler Jason D · CIK 0001554974 · Pres., International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,528 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 02, 2018 Filed Nov 6, 2018 18:13 UTC | Cigna Holding Co CI · Entity 161580 | Exercise / conversionCommon Stock, $.25 Par Value | 5,268 | $120.90 | $636,874.86 |
DisclosureSEC source: 0001225208-18-015237 · doc4.xml · nonDerivative · entry 1 Sadler Jason D · CIK 0001554974 · Pres., International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,966 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 02, 2018 Filed Mar 6, 2018 18:41 UTC | Cigna Holding Co CI · Entity 161580 | GrantCommon Stock, $.25 Par Value | 6,650 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-005499 · doc4.xml · nonDerivative · entry 1 Sadler Jason D · CIK 0001554974 · Pres., International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,698 F1 · shares: The reported securities are shares of common stock received pursuant to the settlement of strategic performance shares for the 2015-2017 three-year performance period. The number of shares of common stock received was based upon actual performance against pre-established Company performance goals. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 17:26 UTC | Cigna Holding Co CI · Entity 161580 | GrantEmployee Stock Option (Right to Buy) · Derivative | 12,271 | $0.00 Strike: $197.35 | $0.00 |
DisclosureSEC source: 0001225208-18-005176 · doc4.xml · derivative · entry 1 Sadler Jason D · CIK 0001554974 · Pres., International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,271 Underlying: Common Stock, $.25 Par Value · 12,271 shares Expires 2028-02-28 F1 · derivative.exercise_date: This option vests in three equal annual installments beginning February 28, 2019. Read SEC document |
| August 07, 2017 Filed Aug 9, 2017 17:42 UTC | Cigna Holding Co CI · Entity 161580 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 4,864 | $0.00 Strike: $58.73 | $0.00 |
DisclosureSEC source: 0001225208-17-013448 · doc4.xml · derivative · entry 9 Sadler Jason D · CIK 0001554974 · Pres., International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $.25 Par Value · 4,864 shares Expires 2023-03-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option was granted on March 5, 2013. The option vested in three equal annual installments on the first, second and third anniversaries of the grant date. Read SEC document |
| August 07, 2017 Filed Aug 9, 2017 17:42 UTC | Cigna Holding Co CI · Entity 161580 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 4,562 | $0.00 Strike: $139.22 | $0.00 |
DisclosureSEC source: 0001225208-17-013448 · doc4.xml · derivative · entry 8 Sadler Jason D · CIK 0001554974 · Pres., International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,124 Underlying: Common Stock, $.25 Par Value · 4,562 shares Expires 2026-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option vests in three equal annual installments. The first installment became exercisable on March 1, 2017, and the next two installments become exercisable on March 1, 2018 and March 1, 2019. Read SEC document |
| August 07, 2017 Filed Aug 9, 2017 17:42 UTC | Cigna Holding Co CI · Entity 161580 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 13,340 | $0.00 Strike: $78.04 | $0.00 |
DisclosureSEC source: 0001225208-17-013448 · doc4.xml · derivative · entry 7 Sadler Jason D · CIK 0001554974 · Pres., International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $.25 Par Value · 13,340 shares Expires 2024-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option was granted on February 26, 2014. The option vested in three equal annual installments on the first, second and third anniversaries of the grant date. Read SEC document |
| August 07, 2017 Filed Aug 9, 2017 17:42 UTC | Cigna Holding Co CI · Entity 161580 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 10,534 | $0.00 Strike: $120.90 | $0.00 |
DisclosureSEC source: 0001225208-17-013448 · doc4.xml · derivative · entry 6 Sadler Jason D · CIK 0001554974 · Pres., International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,268 Underlying: Common Stock, $.25 Par Value · 10,534 shares Expires 2025-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option vests in three equal annual installments. The first installment became exercisable on February 25, 2016, the second installment became exercisable on February 25, 2017, and the last installment becomes exercisable on February 25, 2018. Read SEC document |
| August 07, 2017 Filed Aug 9, 2017 17:42 UTC | Cigna Holding Co CI · Entity 161580 | SaleCommon Stock, $.25 Par Value | 37,756 | $176.16 | $6,650,998.79 |
DisclosureSEC source: 0001225208-17-013448 · doc4.xml · nonDerivative · entry 5 Sadler Jason D · CIK 0001554974 · Pres., International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,048 F1 · price: Represents the weighted average price of the shares sold. The prices actually received ranged from $175.89 to $176.44 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 07, 2017 Filed Aug 9, 2017 17:42 UTC | Cigna Holding Co CI · Entity 161580 | Exercise / conversionCommon Stock, $.25 Par Value | 4,562 | $139.22 | $635,121.64 |
DisclosureSEC source: 0001225208-17-013448 · doc4.xml · nonDerivative · entry 4 Sadler Jason D · CIK 0001554974 · Pres., International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,804 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 07, 2017 Filed Aug 9, 2017 17:42 UTC | Cigna Holding Co CI · Entity 161580 | Exercise / conversionCommon Stock, $.25 Par Value | 4,864 | $58.73 | $285,662.72 |
DisclosureSEC source: 0001225208-17-013448 · doc4.xml · nonDerivative · entry 3 Sadler Jason D · CIK 0001554974 · Pres., International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,242 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 07, 2017 Filed Aug 9, 2017 17:42 UTC | Cigna Holding Co CI · Entity 161580 | Exercise / conversionCommon Stock, $.25 Par Value | 10,534 | $120.90 | $1,273,507.93 |
DisclosureSEC source: 0001225208-17-013448 · doc4.xml · nonDerivative · entry 2 Sadler Jason D · CIK 0001554974 · Pres., International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,378 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 07, 2017 Filed Aug 9, 2017 17:42 UTC | Cigna Holding Co CI · Entity 161580 | Exercise / conversionCommon Stock, $.25 Par Value | 13,340 | $78.04 | $1,040,986.90 |
DisclosureSEC source: 0001225208-17-013448 · doc4.xml · nonDerivative · entry 1 Sadler Jason D · CIK 0001554974 · Pres., International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,844 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 05, 2017 Filed Jun 7, 2017 18:54 UTC | Cigna Holding Co CI · Entity 161580 | SaleCommon Stock, $.25 Par Value | 1,727 | $164.59 | $284,246.93 |
DisclosureSEC source: 0001225208-17-011009 · doc4.xml · nonDerivative · entry 1 Sadler Jason D · CIK 0001554974 · Pres., International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,504 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 30, 2016. Read SEC document |
| April 10, 2017 Filed Apr 12, 2017 17:22 UTC | Cigna Holding Co CI · Entity 161580 | SaleCommon Stock, $.25 Par Value | 4,213 | $152.01 | $640,418.13 |
DisclosureSEC source: 0001225208-17-008002 · doc4.xml · nonDerivative · entry 1 Sadler Jason D · CIK 0001554974 · Pres., International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,231 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 30, 2016. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 17:48 UTC | Cigna Holding Co CI · Entity 161580 | GrantEmployee Stock Option (Right to Buy) · Derivative | 12,402 | $0.00 Strike: $149.14 | $0.00 |
DisclosureSEC source: 0001225208-17-005395 · doc4.xml · derivative · entry 1 Sadler Jason D · CIK 0001554974 · Pres., International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,402 Underlying: Common Stock, $.25 Par Value · 12,402 shares Expires 2027-02-28 F1 · derivative.exercise_date: This option vests in three equal annual installments beginning February 28, 2018. Read SEC document |
| February 24, 2017 Filed Feb 28, 2017 18:46 UTC | Cigna Holding Co CI · Entity 161580 | GrantCommon Stock, $.25 Par Value | 8,425 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-004970 · doc4.xml · nonDerivative · entry 1 Sadler Jason D · CIK 0001554974 · Pres., International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,444 F1 · shares: The reported securities are shares of common stock received pursuant to the settlement of strategic performance shares for the 2014-2016 three-year performance period. The number of shares of common stock received was based upon actual performance against pre-established Company performance goals. Read SEC document |
| December 20, 2016 Filed Dec 22, 2016 11:39 UTC | Cigna Holding Co CI · Entity 161580 | SaleCommon Stock, $.25 Par Value | 2,000 | $138.10 | $276,200.00 |
DisclosureSEC source: 0001225208-16-043660 · doc4.xml · nonDerivative · entry 1 Sadler Jason D · CIK 0001554974 · Pres., International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,019 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 30, 2016. Read SEC document |
| October 31, 2016 Filed Nov 2, 2016 17:24 UTC | Cigna Holding Co CI · Entity 161580 | SaleCommon Stock, $.25 Par Value | 4,000 | $121.80 | $487,200.00 |
DisclosureSEC source: 0001225208-16-041025 · doc4.xml · nonDerivative · entry 1 Sadler Jason D · CIK 0001554974 · Pres., International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,019 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 30, 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.